L. Diana McKenzie's Insider Trades & SAST Disclosures
L. Diana McKenzie's most recent trade in Metlife Inc was a trade of 144 Common Stock done at an average price of $78.5 . Disclosure was reported to the exchange on March 11, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern L. Diana McKenzie.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 78.45 per share. | 11 Mar 2025 | 144 | 20,810 (0%) | 0% | 78.5 | 11,297 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 81.78 per share. | 02 Jan 2025 | 535 | 20,667 (0%) | 0% | 81.8 | 43,752 | Common Stock |
| Metlife Inc | Diana McKenzie L. | Director | Grant, award, or other acquisition of securities at price $ 82.74 per share. | 16 Dec 2024 | 132 | 20,132 (0%) | 0% | 82.7 | 10,922 | Common Stock |
| Agilon Health Inc | Diana L. McKenzie | Director | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 25 Nov 2024 | 12,500 | 51,319 | - | 2.3 | 28,474 | Common Stock |
| Agilon Health Inc | Diana L. McKenzie | Director | Purchase of securities on an exchange or from another person at price $ 2.20 per share. | 25 Nov 2024 | 7,500 | 58,819 | - | 2.2 | 16,489 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 81.78 per share. | 01 Oct 2024 | 535 | 20,000 (0%) | 0% | 81.8 | 43,752 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 74.63 per share. | 10 Sep 2024 | 141 | 19,465 (0%) | 0% | 74.6 | 10,523 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 69.86 per share. | 18 Jun 2024 | 627 | 19,324 (0%) | 0% | 69.9 | 43,802 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 69.06 per share. | 11 Jun 2024 | 146 | 18,697 (0%) | 0% | 69.1 | 10,083 | Common Stock |
| Agilon Health Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 32,119 | 38,819 | - | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,168 | 5,990 | - | - | Deferred Stock Units | |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 May 2024 | 1,168 | 2,436 (0%) | 0% | - | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,001 | 3,604 (0%) | 0% | 0 | Common Stock | |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 73.69 per share. | 01 Apr 2024 | 594 | 18,550 (0%) | 0% | 73.7 | 43,772 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 71.90 per share. | 14 Mar 2024 | 129 | 17,956 (0%) | 0% | 71.9 | 9,275 | Common Stock |
| Vertex Pharmaceuticals, Inc. | L. McKenzie Diana | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 76 | 4,822 | - | - | Deferred Stock Units | |
| Metlife Inc | L. Diana McKenzie | Director | Grant, award, or other acquisition of securities at price $ 67.35 per share. | 02 Jan 2024 | 650 | 17,828 (0%) | 0% | 67.4 | 43,778 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 66.90 per share. | 14 Dec 2023 | 132 | 17,178 (0%) | 0% | 66.9 | 8,831 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 61.69 per share. | 02 Oct 2023 | 710 | 17,045 (0%) | 0% | 61.7 | 43,800 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 65.93 per share. | 14 Sep 2023 | 128 | 16,335 (0%) | 0% | 65.9 | 8,439 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 89 | 4,656 | - | - | Deferred Stock Units | |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 54.52 per share. | 20 Jun 2023 | 803 | 16,207 (0%) | 0% | 54.5 | 43,780 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 53.94 per share. | 14 Jun 2023 | 147 | 15,404 (0%) | 0% | 53.9 | 7,929 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 1,449 | 4,566 | - | - | Deferred Stock Units | |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 May 2023 | 1,449 | 1,435 (0%) | 0% | - | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 1,168 | 2,603 (0%) | 0% | 0 | Common Stock | |
| Agilon Health Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 5,622 | 6,700 | - | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 90 | 3,117 | - | - | Deferred Stock Units | |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 57.97 per share. | 03 Apr 2023 | 755 | 15,257 (0%) | 0% | 58.0 | 43,767 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 59.07 per share. | 14 Mar 2023 | 121 | 14,502 (0%) | 0% | 59.1 | 7,147 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 71.74 per share. | 28 Feb 2023 | 31 | 14,381 (0%) | 0% | 71.7 | 2,224 | Common Stock |
| Agilon Health Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 11,104 | 11,104 | - | - | Options (Rights to Buy) | |
| Agilon Health Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 1,078 | 1,078 | - | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2023 | 100 | 3,027 | - | - | Deferred Stock Units | |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 72.15 per share. | 03 Jan 2023 | 520 | 14,350 (0%) | 0% | 72.2 | 37,518 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 72.84 per share. | 14 Dec 2022 | 94 | 13,830 (0%) | 0% | 72.8 | 6,847 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Oct 2022 | 101 | 2,926 | - | - | Deferred Stock Units | |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 62.62 per share. | 03 Oct 2022 | 599 | 13,735 (0%) | 0% | 62.6 | 37,509 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 66.41 per share. | 14 Sep 2022 | 98 | 13,136 (0%) | 0% | 66.4 | 6,508 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2022 | 95 | 2,825 | - | - | Deferred Stock Units | |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 62.53 per share. | 21 Jun 2022 | 600 | 13,038 (0%) | 0% | 62.5 | 37,518 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 61.86 per share. | 14 Jun 2022 | 100 | 12,438 (0%) | 0% | 61.9 | 6,186 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 May 2022 | 1,842 | 1,435 (0%) | 0% | - | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2022 | 1,842 | 2,730 | - | - | Deferred Stock Units | |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2022 | 1,449 | 2,884 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2022 | 95 | 888 | - | - | Deferred Stock Units | |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 70.50 per share. | 01 Apr 2022 | 532 | 12,338 (0%) | 0% | 70.5 | 37,506 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 64.69 per share. | 14 Mar 2022 | 87 | 11,806 (0%) | 0% | 64.7 | 5,628 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 119 | 793 | - | - | Deferred Stock Units | |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 63.23 per share. | 03 Jan 2022 | 594 | 11,720 (0%) | 0% | 63.2 | 37,559 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 60.80 per share. | 14 Dec 2021 | 87 | 11,126 (0%) | 0% | 60.8 | 5,290 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2021 | 151 | 674 | - | - | Deferred Stock Units | |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 62.52 per share. | 01 Oct 2021 | 600 | 11,038 (0%) | 0% | 62.5 | 37,512 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 60.78 per share. | 14 Sep 2021 | 82 | 10,438 (0%) | 0% | 60.8 | 4,984 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 138 | 523 | - | - | Deferred Stock Units | |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 63.77 per share. | 15 Jun 2021 | 589 | 10,357 (0%) | 0% | 63.8 | 37,561 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 63.32 per share. | 14 Jun 2021 | 73 | 9,768 (0%) | 0% | 63.3 | 4,622 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2021 | 1,842 | 3,277 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 124 | 384 | - | - | Deferred Stock Units | |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 61.60 per share. | 01 Apr 2021 | 609 | 9,695 (0%) | 0% | 61.6 | 37,514 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 60.54 per share. | 15 Mar 2021 | 69 | 9,086 (0%) | 0% | 60.5 | 4,177 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 121 | 259 | - | - | Deferred Stock Units | |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 46.08 per share. | 04 Jan 2021 | 814 | 9,017 (0%) | 0% | 46.1 | 37,509 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 45.84 per share. | 14 Dec 2020 | 81 | 8,203 (0%) | 0% | 45.8 | 3,713 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2020 | 112 | 138 | - | - | Deferred Stock Units | |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 37.26 per share. | 01 Oct 2020 | 1,007 | 8,121 (0%) | 0% | 37.3 | 37,521 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 38.84 per share. | 14 Sep 2020 | 83 | 7,114 (0%) | 0% | 38.8 | 3,224 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2020 | 26 | 26 | - | - | Deferred Stock Units | |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 38.69 per share. | 16 Jun 2020 | 970 | 7,031 (0%) | 0% | 38.7 | 37,529 | Common Stock |
| Metlife Inc | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 37.45 per share. | 12 Jun 2020 | 74 | 6,061 (0%) | 0% | 37.4 | 2,771 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Diana L. McKenzie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2020 | 1,435 | 1,435 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges